Yan Mei et al. [28] investigated the proliferative activity and antigen-presenting capacity of CD19+ and CD20+ B cells and found that their proliferation states were higher and more dispersed in tumoral tissue comparing with adjacent and precancerous tissues and that CD40+ and CD27+ B cells had diminished antitumor immunity capacity in CRC. This evidence concerns the gene CD40 and colorectal carcinoma.